Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,032 recruiting studies in this area right now.
By phase
- Not applicable2,815
- Phase 2751
- Phase 1525
- Phase 3381
- Phase 1/Phase 2297
- Phase 4204
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,197
- Melanoma174
- Metastatic Breast Cancer138
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Breast Neoplasms111
- Triple Negative Breast Cancer110
- Colorectal Cancer95
- Ovarian Cancer91
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer60
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Memorial Sloan Kettering Cancer Center49
- Novartis Pharmaceuticals48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University34
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona150
- Alabama130
- Florida128
- New York110
- Texas106
- Maryland94
- Massachusetts86
- Pennsylvania72
- North Carolina68
Recruiting studies5,032 total
- NCT05782335Recruiting
Study immune cell changes with Orencia in rheumatoid arthritis
This trial studies how Orencia (abatacept) affects your immune system’s T and B cells in people with rheumatoid arthritis. It may help researchers better understand who responds to Orencia and what immune changes happen over time.
New York, New YorkAges 18 years+ - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05779423RecruitingPhase 2
Freezing tumor plus two immunotherapies for advanced melanoma
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Boston, MassachusettsAges 18 years+ - NCT05799378RecruitingPhase 3
Stopping hydroxychloroquine in older adults with stable lupus
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
Los Angeles, CaliforniaAges 55 years+ - NCT05794945Recruiting
Study to improve mastitis detection and treatment
This study aims to better identify and treat mastitis (breast inflammation or infection) in pregnant people. You may be asked to answer questionnaires and provide samples so researchers can learn what signals help guide care.
Tromsø, TromsAges 18–50 - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05789056RecruitingPhase 2/Phase 3
Study lotion for Netherton syndrome safety and symptom improvement
This trial tests a prescription lotion (QRX003) to see if it is safe and helpful for people with Netherton syndrome. Because the study checks skin symptoms on certain body areas and closely controls other treatments, it may be best for patients who can keep their current regimen stable.
San Diego, CaliforniaAges 14 years+ - NCT05805137Recruiting
Bioimpedance monitoring for venous leg ulcers under compression
This study tests a skin-measurement method (bioimpedance) to monitor how venous leg ulcers heal while using standard compression therapy. It may help the study team track healing sooner and more accurately so treatment can be adjusted if needed.
TampereAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT05750901Recruiting
Laser treatment study for loose skin or scars
This study tests a laser procedure to improve visible skin looseness or scars. You may be eligible if you have a targeted skin area needing treatment and can follow scheduled visits and after-care.
Boca Raton, FloridaAges 18–85 - NCT05758545Recruiting
Device treatment for diabetic foot ulcers with poor blood flow
This trial tests whether COMS One is safe and effective for healing a specific diabetic foot ulcer. It may help people whose ulcer is not healing well, especially when blood flow to the foot is limited.
Mesa, ArizonaAges 22–90 - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05774678RecruitingPhase 3
Pre-surgery radiation options for invasive breast cancer
This trial compares two schedules of radiation given before mastectomy to see which works better for invasive breast cancer, followed by immediate breast reconstruction. It also studies tiny “biomarker” signals in tissue to learn why one radiation approach may help more.
Houston, TexasAges 18 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05753618RecruitingPhase 4
Skipping growth-factor shots during breast cancer chemotherapy
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
Kingston, OntarioAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05758181Enrolling by invitation
Testing a dressing on surgical wounds to help healing
This study looks at how a wound dressing or treatment affects healing in surgical cuts that are closed with sutures or similar methods. You may be able to join if you’re having a skin surgery on the neck, trunk, or arms/legs with a long enough wound you can follow up on.
Sacramento, CaliforniaAges 18 years+ - NCT05762432Recruiting
Wound dressing study for certain diabetic foot ulcers
This study looks at a specific wound dressing in people with a non-infected diabetic foot ulcer that has nerve pain (neuropathic), poor blood flow (ischemic), or both. It may help you heal the ulcer and improve how the wound looks and progresses.
Airdrie, North LanarkshireAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,032 recruiting dermatology studies from the U.S. registry right now, out of 7,856 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.